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Alternative cleavage and polyadenylation (ApA) is known to alter untranslated region
(3ʹUTR) length but can also recognize intronic polyadenylation (IpA) signals to generate
transcripts that lose part or all of the coding region. We analyzed 46 3ʹ-seq and RNA-seq
proﬁles from normal human tissues, primary immune cells, and multiple myeloma (MM)
samples and created an atlas of 4927 high-conﬁdence IpA events represented in these cell
types. IpA isoforms are widely expressed in immune cells, differentially used during B-cell
development or in different cellular environments, and can generate truncated proteins
lacking C-terminal functional domains. This can mimic ectodomain shedding through loss of
transmembrane domains or alter the binding speciﬁcity of proteins with DNA-binding or
protein–protein interaction domains. MM cells display a striking loss of IpA isoforms
expressed in plasma cells, associated with shorter progression-free survival and impacting
key genes in MM biology and response to lenalidomide.
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A lternative cleavage and polyadenylation (ApA) is generallyviewed as the selection of ApA signals in the 3ʹ untrans-lated region (3ʹUTR), leading to the expression of dif-
ferent 3ʹUTR isoforms that code for the same protein. Recent
computational analyses of 3ʹ-end sequencing data have char-
acterized the nature and extent of ApA in mammalian 3ʹUTRs1–7.
For example, analysis of a human ApA tissue atlas established
that half of human genes express multiple 3ʹUTRs, enabling
tissue-speciﬁc post-transcriptional regulation of ubiquitously
expressed genes1. However, ApA events can also occur in introns
rather than 3ʹUTRs, generating either non-coding transcripts or
transcripts with truncated coding regions that lead to loss of
C-terminal domains in the protein product.
The most famous example of cell type-speciﬁc usage of an
intronic polyadenylation (IpA) signal occurs in the immunoglo-
bulin M heavy chain (IGHM) locus8,9. In mature B cells, recog-
nition of the polyadenylation signal in the 3ʹUTR produces the
full-length message, including two terminal exons that encode the
transmembrane domain of the plasma membrane-bound form of
immunoglobulin M (IgM; Fig. 1a). In plasma cells, usage of an
IpA signal instead results in expression of an IpA isoform lacking
these two terminal exons, leading to loss of the transmembrane
domain and secretion of IgM antibody. Many additional IpA-
generated truncated proteins have been described10,11, including
the soluble forms of epidermal growth factor and ﬁbroblast
growth factor receptors and a truncated version of the tran-
scription factor NFI-B12. The IpA isoform of the interferon-
induced anti-viral enzyme OAS1 generates an enzyme of com-
parable enzymatic activity as the full-length transcript but con-
tains a hydrophobic C terminus rather than an acidic C terminus,
suggesting that the two isoforms may interact with different co-
factors or cellular structures13. Other examples include the
transcription factor SREPF, whose IpA isoform can act as a
developmental switch during spermatogenesis14.
In the splicing literature, isoforms generated through recog-
nition of an IpA signal are often described as ‘alternative last
exon’ events15. Genes that generate IpA isoforms are thought to
harbor competing splicing and polyadenylation signals, produ-
cing a full-length messenger RNA (mRNA) when splicing out-
competes polyadenylation and otherwise producing a truncated
mRNA16. As the deﬁning event is the recognition of an IpA
signal, we call these transcripts IpA isoforms. It is now possible to
recognize the widespread expression of IpA isoforms through the
analysis of 3ʹ-end sequencing data.
We identiﬁed robust ApA events that occur in introns and
quantiﬁed IpA isoform expression using 3ʹ-seq across human
tissues, immune cells, and in multiple myeloma (MM) patient
samples. We focused on immune cells because it is feasible to
obtain pure populations of primary cells and because B cells
expressed the largest number of IpA isoforms in our
previous tissue atlas1. Through integration with RNA-seq proﬁles
in B-lineage and MM cells as well as external data sets and
annotation databases, we assembled an atlas of conﬁdent IpA
isoforms supported either by independent data sources or very
highly expressed in at least one cell type. We found
that IpA isoforms are widely expressed, most prevalently in
blood-derived immune cells, and that generation of IpA isoforms
is regulated during B-cell development, between cellular envir-
onments, and in cancer. IpA events in immune cells are enriched
at the start of the transcription unit, leading to IpA isoforms that
retain none or little of the coding region (CDR) and hence
represent a class of robustly expressed non-coding transcripts.
IpA events that occur later in transcription units can lead to
truncated proteins often lacking repeated C-terminal functional
domains and thus contribute to the diversiﬁcation of the
proteome.
Results
3ʹ-seq analysis reveals widespread intronic polyadenylation. To
assemble an atlas of IpA isoforms, we used our previously pub-
lished 3ʹ-seq data set from normal human tissues (ovary, brain,
breast, skeletal muscle, testis), cell types (embryonic stem (ES)
cells, naive B cells from peripheral blood (blood NB)), and cell
lines1 and combined it with a newly generated data set from
normal and malignant primary immune cells. The new immune
cell proﬁles (n= 29) were all performed with biological replicates
and included lymphoid tissue-derived naive B cells (NB), memory
B cells (MemB), germinal center B cells (GCB) and CD5+ B cells
(CD5+B), blood T cells and plasma cells (PCs), and MM derived
from bone marrow aspirates (Supplementary Tables 1 and 2). We
adapted our previously described computational pipeline to
process 3ʹ-seq libraries and detect and quantify ApA events,
including intronic as well as 3ʹUTR events, while removing
technical artifacts (see Methods)1. All subsequent analyses were
restricted to protein coding genes. For additional evidence in
support of IpA isoforms, we performed RNA-seq proﬁling in the
same normal and malignant B cell types, where possible for the
same samples (Supplementary Table 3).
We conﬁrmed from both 3ʹ-seq and RNA-seq data that the IpA
isoform of IGHM is highly expressed in PCs while the full-length
transcript, encoding membrane-bound IgM, is the dominant
isoform in NB cells (Fig. 1b). Analysis of 3ʹ-seq also revealed
putative IpA isoforms, including in the locus of GTF2H1,
encoding a subunit of general transcription factor II H, and
RAB10, encoding a member of the Ras oncogene family of small
GTPases (Fig. 1c). Like 3ʹUTR isoforms, IpA isoforms display
differential expression across tissues and cell types. For example,
the IpA isoform of GTF2H1 is well expressed in skeletal muscle
and immune cells, and indeed is the only isoform expressed in
PC, blood NB, and T cells; these three cell types are also the only
ones to express the IpA isoform of RAB10. To validate IpA events
identiﬁed by 3ʹ-seq, we used RNA-seq data from the same cell
types to conﬁrm intronic read coverage upstream but not
downstream of the IpA event, as in PC RNA-seq coverage
ﬂanking the intronic 3ʹ-seq peak in GTF2H1 (Fig. 1d). Formally,
we can test if RNA-seq read counts are signiﬁcantly higher in
intronic windows chosen upstream compared to downstream of
IpA events (see Methods)17. We conﬁrmed signiﬁcantly differ-
ential coverage at 29% (n= 1670) of IpA events from our 3ʹ-seq
peak calls (false discovery rate (FDR)-adjusted P < 0.1) versus
almost no signiﬁcant differences at randomly chosen positions in
introns (Supplementary Fig. 1a).
To assemble an atlas of conﬁdent IpA events, we compared
each intronic 3ʹ-seq peak against external annotation and data
sources (see Methods, Supplementary Fig. 1b,c). Brieﬂy, IpA
events that overlapped with the last exon of annotated isoforms in
RefSeq, UCSC (University of California Santa Cruz), and
Ensembl were ﬁrst added to the atlas (2241 events); unannotated
IpA events that satisﬁed the test for differential upstream vs.
downstream RNA-seq coverage were added next (907 events);
unannotated IpA events without differential RNA-seq coverage
but supported in data sets from other 3ʹ-end sequencing protocols
were then included (1332 events)18. We next added IpA events
that lacked the previous sources of evidence but had RNA-seq
support of the cleavage event—i.e., reads overlapping untem-
plated adenosines in the polyA tail (124 events). Finally, events
with high expression in at least one cell type were also included
(323 events). 13% (n= 743) of IpA events could not be validated
by any of these criteria and thus were excluded from further
analysis (Supplementary Fig. 1c). Overall, the atlas contains 4927
conﬁdent IpA events in 3431 protein coding genes, 55% of which
are unannotated in RefSeq, UCSC, and Ensembl (Supplementary
Fig. 1c). Similar proportions of annotated and unannotated IpA
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isoforms were validated by various kinds of supporting evidence
(Fig. 1e). Although we used other 3ʹ-end sequencing data sets as
an evidence source, only 54% (2677/4927) of IpA atlas events
appear in polyA_DB 3 (http://exon.umdnj.edu/polya_db/), a
resource based on 3ʹREADS data18, and 72% (3581/4927) have
support from existing PolyA-seq, as they do not include the
immune cell types that we proﬁle here. Therefore, while our atlas
does not exhaustively sample human tissues, we have assembled
the most comprehensive IpA resource to date.
IpA is most prevalent in circulating immune cells. We deter-
mined the prevalence of IpA across normal tissues and cell types
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by computing the fraction of genes expressing at least one atlas
IpA isoform out of all expressed genes in each cell type (Fig. 1f).
Blood T cells had the highest fraction of genes with IpA isoforms
(0.16) while ovary had the lowest fraction (0.04). In immune cells,
6–16% of genes expressed generate IpA isoforms compared to
only 4–8% of genes in complex tissues, consistent with early IpA
studies that used complementary DNA (cDNA) and
EST (expressed sequence tag) data19,20. Notably, blood NB cells
expressed 1114 IpA isoforms compared to only 721 IpA isoforms
for tissue-derived NB cells, suggesting that the cellular environ-
ment has a strong effect on IpA isoform expression.
IpA isoforms are robustly expressed, with median expression of
the same order of magnitude as for full-length isoforms (log2 tags
per million (TPM) of 3.71–3.83 for IpA isoforms in PCs, blood
NB, and blood T versus log2 TPM of 4.53–5.15 for full-length
transcripts; Fig. 1g). Therefore, IpA isoforms are not ‘transcrip-
tional noise’ produced from recognition of ‘cryptic’ sites, but
rather represent major mRNA isoforms generated from alter-
native mRNA processing.
Figure 1h shows the tissue-speciﬁc expression of IpA isoforms,
requiring a mean isoform expression level over 5 TPM across
replicates to be considered ‘expressed’. A majority of IpA
isoforms with reproducible expression patterns are expressed in
immune cell types (n= 3365), and almost all of these in at least
two immune cell types. Non-immune tissues like testis and ES
cells express tissue-speciﬁc IpA isoforms, but the majority are
produced from tissue-speciﬁc genes.
Cell types with frequent IpA express shorter isoforms. To begin
to assess the impact of IpA isoform expression, we computed the
fraction of retained CDR for each IpA isoform relative to the full-
length annotated CDR. The histogram of retained CDR fraction
for atlas events showed a uniform distribution except for a sub-
stantial overrepresentation of IpA isoforms that lose all or almost
all of the CDR (Fig. 2a). However, an examination of similar
histograms across individual tissues and cell types revealed a
more nuanced picture (Fig. 2b), where IpA events near the start of
the transcription unit dominate in blood and bone marrow-
derived immune cells, while brain and ES cells preferentially
generate IpA events close to the end of transcription units. In
testis and tissue-derived B cells, we found an intermediate
pattern.
We observed a signiﬁcant negative correlation across tissues
between the frequency of IpA isoform expression and length of
retained CDR (r=−0.86, Fig. 2c). Further, cell types with a
tendency to produce longer 3ʹUTRs also prefer to use IpA events
near the 3ʹ ends of transcription units (r= 0.60, Fig. 2d).
We use the term 5ʹIpA for IpA isoforms that retain less than
25% of the CDR and 3ʹIpA for the remainder. Both 5ʹIpA and
3ʹIpA events occur in introns that are signiﬁcantly longer than the
introns from the same genes that contain no IpA events or from
genes that only express full-length transcripts (one-sided
Wilcoxon rank-sum test, P < 10−20 for all three comparisons,
Fig. 2e)20. Similarly, 5ʹIpA and 3ʹIpA isoforms are expressed from
signiﬁcantly longer transcription units than non-IpA genes (one-
sided Wilcoxon rank-sum test, P < 10−20 for both comparisons,
Fig. 2f). 3ʹIpA atlas events have higher conservation by PhastCons
in the sequence surrounding the polyadenylation signal compared
to 5ʹIpA atlas events (one-sided Wilcoxon signed-rank test, P < 10
−66; Fig. 2g); however, 5ʹIpA events still show higher conservation
than randomly chosen intronic polyadenylation signals with no
3ʹ-seq coverage (one-sided Wilcoxon signed-rank test, P < 10−68;
Fig. 2g)21.
An early study using cDNA and EST data20 deﬁned two types
of IpA isoforms based on the structure of the terminal exon:
‘composite terminal exon’, where a donor splice site (5ss) is not
recognized and the entire sequence from this donor splice site to
the intronic cleavage site is included in the isoform; and ‘skipped
terminal exon’, where the IpA isoform introduces a new small
exon ending at the intronic cleavage site, requiring recognition of
the previous donor splice site and a new acceptor splice site
(Supplementary Fig. 2a). Through de novo assembly of RNA-seq
data and comparison to 3ʹ-seq in common cell types, we
assembled the transcript structure for 2675 IpA atlas isoforms
(see Methods). Of these, 1648 (61.6%) displayed loss of
recognition of a donor splice site with ‘composite’ terminal exon,
while the remainder introduced a new exon.
Interestingly, skipped terminal exon IpA isoforms predomi-
nantly use 5ʹIpA sites while composite terminal exon IpA sites
occur throughout the transcription unit (Supplementary Fig. 2b).
Skipped terminal exon IpA sites occur in much longer introns
than those with composite terminal exon IpA sites or introns of
non-IpA genes (one-sided Wilcoxon rank-sum test, P < 10−20,
Supplementary Fig. 2c)20. Both kinds of IpA events occurred in
genes with longer transcription units than non-IpA genes (one-
sided Wilcoxon rank-sum test, P < 10−20, Supplementary Fig. 2c).
Findings about the relative strengths of 5ss and 3ss signals were
largely consistent with the earlier study (Supplementary Fig. 2d)
22. Finally, 84% of skipped terminal exon IpA events and 80% of
composite terminal exon IpA events are associated with
AAUAAA/AUUAAA.
Previously, U1 small nuclear ribonucleoprotein (snRNP)
expression and the presence of U1 snRNP motifs early in the
transcription unit were found to play a crucial role in preventing
premature cleavage and polyadenylation23,24. Consistent with
these observations, we found that genes that express IpA isoforms
contain a higher frequency of polyadenylation signals within their
transcription unit and are depleted for U1 snRNP signals, as
compared to genes that only express 3ʹUTR isoforms (Fig. 2h, i).
To control for background AT content, we divided both IpA
genes and non-IpA genes into those falling in high AT (AT
Fig. 1Widespread intronic polyadenylation in immune cells. a Schematic representation of full-length and IpA isoform of IGHM expressed in mature B cells
and plasma cells (PC). b The 3ʹ-seq (tags per million (TPM)) and RNA-seq (read coverage) tracks showing expression of the IpA and full-length mRNA
isoforms of IGHM (ENSG00000211899), encoding the immunoglobulin mu heavy chain, IgM. The full-length isoform is expressed in NB from blood and
lymphoid tissue and includes two exons encoding the C-terminal transmembrane domain of membrane-bound IgM. The IpA isoform is expressed in PCs
obtained from bone marrow. It lacks the transmembrane domain which leads to expression of soluble IgM. c The 3ʹ-seq tracks showing IpA isoform
expression for two genes across human tissues and immune cell types. d RNA-seq coverage of intronic regions ﬂanking IpA sites. A GLM-based test is
used to validate the IpA isoforms. An isoform is considered validated if there is a signiﬁcant difference (FDR-adjusted P < 0.1) in read counts in windows
located up- and downstream of the putative IpA site. e The fraction of IpA isoforms validated by read evidence from independent data sets is shown for
annotated and unannotated IpA isoforms. IpA isoforms present in RefSeq, UCSC genes, and Ensembl databases are considered to be annotated. f The
fraction of expressed genes that generate IpA isoforms is shown for each cell type. g Expression levels (log2 TPM) for full-length mRNAs and IpA isoforms
are shown as boxplots for in PCs, blood NB, and T cells. IpA isoforms are robustly expressed as full-length mRNA expression is 4.53, 5.15, and 5.11,
respectively, compared to 3.71, 3.83, and 3.71 for IpA isoforms. h Tissue-speciﬁc expression of IpA isoforms. Each row represents a gene. Dark blue, IpA
isoform is expressed (≥5 TPM); light blue, IpA isoform is not expressed, but full-length mRNA is expressed (≥5.5 TPM); and white, gene is not expressed
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(one-sided Wilcoxon signed-rank test, P < 10−68 for both comparisons). h Genes with IpA isoforms (n= 3481) are enriched for polyadenylation sites
compared with genes that do no generate IpA isoforms (n= 12,092) (one-sided Wilcoxon signed-rank test, P < 10−18). The frequency of polyadenylation
sites was counted from the TSS to the beginning of the 3ʹUTR and is shown as the average number of signals per kb per gene. i As in h, but U1 binding sites
are shown. IpA genes are depleted for U1 snRNP signals (one-sided Wilcoxon signed-rank test, P < 10−18)
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content > 50%) versus low AT (AT content < 50%) regions and
repeated the polyadenylation and U1 signal analysis (Supple-
mentary Fig. 2e). We again found signiﬁcant enrichment of
polyadenylation signals in IpA genes vs. non-IpA genes in both
high and low AT regions as well as depletion of U1 signals (one-
sided Wilcoxon signed-rank test, P < 10−10 for all four
comparisons), although the effect sizes were more modest.
However, IpA genes have high AT content compared to the
genes lacking IpA events, so AT content is enough to segregate
IpA genes from non-IpA genes (Supplementary Fig. 2f, Wilcoxon
rank-sum test, P < 10−20). Therefore, genomic architecture and
sequence composition may facilitate IpA isoform expression, but
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high background AT content is also strongly associated with IpA
genes.
IpA usage leads to modest full-length mRNA downregulation.
Next we used a generalized linear model (GLM) approach to
determine signiﬁcant changes in the relative expression of IpA
isoforms compared to full-length transcripts (usage of IpA) across
normal immune cells (see Methods)1,17,25. A majority of
expressed IpA isoforms signiﬁcantly differed in usage between NB
cells from lymphoid tissue and blood T cells (950/1308, Fig. 3a,
FDR-adjusted P < 0.05, Supplementary Data). We also found
differential IpA usage between B-lineage cell types, with PCs in
particular showing strikingly increased IpA site usage compared
to tissue-derived NB cells (Fig. 3a). However, surprisingly, we
found even more signiﬁcant changes in IpA usage between NB
cells from lymphoid tissue and blood (720/1113, Supplementary
Data) than between different B-cell types (Fig. 3a, b). Thus, IpA
isoform expression is not only cell-type differential but also
changes between different cellular environments. Genes with
differential usage of IpA isoforms between immune cell types
were most strongly enriched for annotations including zinc-ﬁnger
domains, bromodomains, and the ubiquitin-like conjugation
pathway (Fig. 3c)26.
Figure 3d plots the expression change of the IpA isoform
against that of the full-length transcript and shows IpA genes that
differentially increase (red points) or decrease (blue points) usage
of their IpA isoforms in blood-derived compared with tissue-
derived NB cells. Genes that increase IpA isoform usage in blood-
versus tissue-derived NB cells signiﬁcantly reduce expression of
their full-length transcripts compared to genes without signiﬁcant
change in IpA usage (Fig. 3e, one-sided Kolmogorov–Smirnov
(KS) test, P < 10−5). However, the decrease in full-length isoform
expression was modest, indicating that IpA usage does not
predominantly result in a ‘switch-like’ change between full-length
and IpA isoform expression.
IpA diversiﬁes the transcriptome by C-terminal domain loss.
We next observed that IpA genes encode full-length proteins that
are signiﬁcantly larger and contain more domains than non-IpA
genes (Fig. 4a, median number of amino acids 588 vs. 432; Fig. 4b,
median 5 vs. 4 domains). Notably, most IpA-generated truncated
proteins still retain functional protein domains, suggesting that
IpA helps diversify the transcriptome (Fig. 4b, median 2
domains). IpA genes preferentially encode proteins with RNA- or
DNA-binding or protein–protein interaction (PPI) domains but
avoid membrane proteins. Proteins encoded by IpA genes are also
enriched in repeated domains (Supplementary Fig. 3a, Fig. 4c),
which in a majority of cases are partially lost through IpA. For
example, the full-length protein encoded by NFKBID has six
ankyrin domains, while the IpA-generated truncated protein
retains four of them. Similarly, the full-length protein of the
transcription factor PATZ1 has seven zinc-ﬁnger domains, while
different IpA isoforms are predicted to encode either four or ﬁve
zinc-ﬁngers (Fig. 4d). The partial loss of DNA-binding domains
potentially changes DNA-binding speciﬁcity and therefore the set
of regulated target genes. Similarly, the partial loss of PPIs can
change the binding afﬁnity to protein interaction partners.
Among genes with a single IpA event and whose IpA isoform
retains at least one protein domain (n= 1405), IpA results in a
preferential loss of DNA-binding or PPI domains but avoids the
loss of active sites (Supplementary Fig. 3b,c and see Methods).
Loss of an active site, where substrate binding and catalysis take
place, would make an enzyme dysfunctional, but IpA appears to
avoid this outcome. IpA genes encode diverse proteins with
enzymatic functions, including protein kinases, DNA or RNA
helicases, or motor proteins (Fig. 4e). The IpA-generated
truncated proteins retain their active sites but lose PPI domains,
which may enable the enzymes to participate in different protein
complexes or change the substrate. For example, the full-length
protein kinase RIPK1 contains a C-terminal death domain that is
excluded in RIPK1 IpA (Fig. 4e). BAZ1B, also called WSTF, is a
multi-functional protein that contains an N-terminal protein
kinase domain but can exclude C-terminal located coiled-coil,
zinc-ﬁnger, and bromodomains. Also, helicases, including
DDX21, DDX49, and DHX15, as well as motor proteins such
as KIF20B retain their enzymatic function but generate proteins
lacking interaction domains.
Membrane proteins are characterized by the presence of
transmembrane domains (TMDs) and are signiﬁcantly depleted
among IpA genes (Fig. 4c, Supplementary Fig. 3a). Nevertheless,
we found 673 IpA isoforms from 499 genes that encode
transmembrane proteins and retain at least one protein domain.
Among them, 207 IpA isoforms from 152 genes completely
retained their TMDs, whereas 220 IpA isoforms from 175 genes
lost their TMDs. Interestingly, IpA isoforms that retain the TMDs
often encode intracellular membrane proteins that localize to
mitochondria. In contrast, IpA isoforms that lose their TMDs are
signiﬁcantly enriched in signal peptides that are predominantly
present in plasma membrane proteins (FDR, P < 9.1 × 10−29,
Fig. 4f, see Methods). Many of them encode cytokine receptors,
integrins, or growth factor receptors. Notably, regardless of the
position of the TMD, the truncated protein generated by IpA
usually terminates immediately before the TMD (Fig. 4g). As all
of these candidates contain signal peptides at the N terminus, the
IpA isoform produces a secreted form of the cytokine or growth
factor receptor.
5ʹIpA can produce robustly expressed non-coding RNAs. A
large fraction of IpA isoforms that are differentially used among
normal immune cell types are in fact 5ʹIpA isoforms (487 out of
1281). Through de novo RNA-seq assembly, we were able to
resolve the transcript structure for 954 of the 5ʹIpA isoforms (see
Methods) and found that 469 of these have low predicted coding
potential with open reading frames (ORFs) encoding fewer than
100 amino acids27. Therefore, they likely generate micropeptides
or represent non-coding RNAs (Fig. 5, Supplementary Fig. 4)28–
31. To assess potential functional consequences of these non-
coding transcripts, we examined if RNA-binding proteins may
preferentially bind to the exonized intronic sequences upstream
of the IpA cleavage site. As shown in Fig. 5, the new exons are
Fig. 4 IpA isoforms diversify the proteome. a Genes that express IpA isoforms encode signiﬁcantly larger proteins compared to genes that only express
full-length mRNAs (one-sided Wilcoxon rank-sum test, P < 10−118); *P < 0.01; **P < 10-5; ***P < 10-10. b Genes that express IpA isoforms encode proteins
with signiﬁcantly more protein domains than genes that only express full-length mRNAs (one-sided Wilcoxon rank-sum test, P < 10−14). IpA isoforms
retain a median of two domains. c Genes that express IpA isoforms are enriched in proteins encoding RNA- and DNA-binding, PPI repeated domains and
active sites compared to genes that only express full-length mRNAs. However, IpA genes are depleted for proteins encoding transmembrane domains
(TMDs). d Protein models of full-length and IpA-generated truncated proteins are shown in gray for examples that contain repeated domains. Known
protein domains are shown as blue boxes and repeated domains are numbered. e As in d, but shown for enzymes that retain their active sites but lose PPI
domains. f As in d, but shown for plasma membrane proteins. The TMD is indicated by the loops. g Distance between the IpA event and the start of the
TMD in IpA isoforms that completely lose their TMDs (n= 272)
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enriched for cross-linking immunoprecipitation (CLIP)-seq peaks
for RNA-binding proteins such as FUS, ELAVL1, PUM2, TAF15,
and TIAL1 (binomial Z > 10, see Methods), which are typically
enriched in the 3ʹUTRs of coding transcripts, but not for RNA-
binding proteins usually bound to introns, supporting the exonic
nature of the predicted non-coding transcripts.
Multiple myeloma displays a widespread loss of plasma cell
IpA isoforms. As alternative 3ʹUTR isoform expression can be
altered in cancer cells6,32,33, we investigated whether IpA is also
dysregulated in cancer. Since PCs express the highest number of
IpA isoforms among the tissue-derived B cells, we compared IpA
isoform expression between normal and malignant PCs, derived
from MM patients (n= 15). As MM is a heterogeneous disease,
we used hierarchical clustering based on IpA isoform expression
to deﬁne three patient subgroups (Supplementary Fig. 5a and
Supplementary Table 2). We then performed GLM modeling as
described above to determine the differential relative expression
of IpA isoforms versus full-length isoforms for each MM group
compared to normal PCs. Whereas one patient group had an IpA
proﬁle comparable to normal PCs, two MM patient groups
showed widespread loss of usage of PC IpA events (groups 1 and
2, Fig. 6a). We found that 44% of all PC-expressed IpA isoforms
(480/1088, Supplementary Data) are lost in at least one patient
group, while only 15 IpA sites show increased usage (FDR-
adjusted P < 0.05). The signiﬁcant events in patient group 1 lar-
gely represent a superset of those in group 2 (Fig. 5b).
Loss of IpA isoform expression in patient group 1 resulted in a
signiﬁcant increase of full-length mRNA expression (Fig. 6b, c).
Genes with differential IpA usage in MM versus PC were again
enriched for annotations such as bromodomain, transcriptional
regulation, and ubiquitin-like conjugation pathway. In the
majority of patient samples proﬁled (11 out of 15), the MM
transcriptome is characterized by the loss of 480 IpA isoforms
that are normally expressed in PCs. This is in contrast to 3ʹUTR
regulation, where we found shortening of 3ʹUTRs in 126 and
lengthening of 3ʹUTRs in 215 multi-UTR genes (MM group 1).
To investigate whether IpA isoform expression is correlated
with any clinical factor, we examined a cohort of 286 MM
patients with RNA-seq proﬁles and clinical information from a
separate study34. Before proceeding, we established a set of IpA
isoforms whose expression from 3ʹ-seq is robustly represented by
RNA-seq signal in the original 12 MM patients (see Methods).
While RNA-seq signal is often not an accurate readout of IpA
isoform expression levels (Supplementary Fig. 6a), we selected
IpA isoforms with high correlation between RNA-seq and 3ʹ-seq
(Pearson's r > 0.75, n= 28) to use as a signature for the extent of
IpA loss in the larger RNA-seq cohort.
Hierarchical clustering with respect to the signature IpA events
segregated the 286 patients largely into two groups (see Methods,
Supplementary Fig. 6b,c), group A (n= 126) with low median
IpA usage and group B (n= 160) with high median IpA.
Interestingly, group B patients, whose IpA usage is more similar
to normal PCs, have improved progression-free survival (P <
0.05) compared to group A patients (Supplementary Fig. 6d).
Since we noticed some heterogeneity in the groups, we applied a
k-nearest-neighbor ﬁlter (see Methods) to remove patients whose
neighbors had inconsistent cluster assignment. This improved the
contrast between low IpA group A-ﬁltered (n= 64) and high IpA
group B-ﬁltered patients (n= 100, Supplementary Fig. 6e) and
difference in progression-free survival (P < 0.028, Fig. 6d). This
analysis suggests either that IpA isoform loss is associated with
faster progression or represents a more advanced disease state
compared to MM cells that still express PC IpA isoforms.
Interestingly, one of the genes that displays loss of IpA
isoform expression is the transcription factor IKZF1, a key gene
in MM biology and the target of Cereblon-mediated degrada-
tion induced by lenalidomide, a MM therapeutic derived from
thalidomide (Fig. 6e)35,36. The IpA isoform of IKZF1 loses all
zinc-ﬁnger domains encoded by the full-length transcript,
potentially leading to expression of a truncated protein isoform
with no known domain. While the IpA isoform is the dominant
isoform in PC, it is almost completely lost in MM group 1
patients, which instead aberrantly express the full-length
transcript. The gene CUL4A encodes a component of the
DDB1-CUL4A-ROC1 E3 ubiquitin ligase complex involved in
Cereblon (CRBN)-mediated degradation of IKZF1 by lenalido-
mide35. The IpA isoform of CUL4A is translated into a
truncated protein (1–174 amino acids) that retains only its N-
terminal domain (Fig. 6e). CUL4A is overexpressed/ampliﬁed in
other cancers37–40 and restricts cellular DNA damage repair41,
and sensitivity to thalidomide correlates with CUL4A expres-
sion in prostate cancer cell lines42. Similarly, the gene encoding
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IQGAP1, a GTPase-activating scaffold protein involved in cell
proliferation in MM, largely loses IpA isoform expression in
MM43. This isoform lacks its Ras-GTP domain as well as most
functional domains and is either non-coding or at best
produces a truncated protein with only a fraction of the N-
terminal actin-binding domain (Fig. 6e). We validated the
relative expression of IKZF1, CUL4A, and IQGAP1 IpA
isoforms at the mRNA level in our cohort of 15 MM patient
samples and normal PCs by quantitative reverse transcription
polymerase chain reaction (qRT-PCR; Fig. 6f). The ratio of IpA
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usage by qRT-PCR is concordant with 3ʹ-seq, conﬁrming the
loss of IpA isoforms in a group of MM patients.
The expression of IpA isoforms of IKZF1 and CUL4A may
have important implications for the response of normal PCs and
some MM patients to lenalidomide treatment. The Cereblon
degron sequence is in a zinc-ﬁnger domain of IKZF1 (Supple-
mentary Fig. 7a), and therefore the IpA isoform that is
predominantly expressed in normal PCs cannot be targeted by
lenalidomide. In fact, while lenalidomide effectively depletes
malignant PCs, it is known to have little effect on normal PCs.
The DDB1-CUL4A-ROC1 crystal structure shows that the N-
terminal region of CUL4A interacts with DDB1 while the C-
terminal region interacts with ROC1, which recruits the E2
ubiquitin-conjugating enzyme (Supplementary Fig. 7b, top)44.
Furthermore, a truncated CUL4A (residues 1–297) has been
shown to act in a dominant negative manner45. The CUL4A-IpA
isoform retains its N-terminal domain and hence the potential to
interact with DDB1 (Supplementary Fig. 7b, bottom). Based on
these observations, we hypothesize that CUL4A-IpA may have
the potential to act in a dominant negative manner in patients
who express the CUL4A-IpA isoform (group 3 from Fig. 6a).
Discussion
IpA isoform expression has previously been viewed as a form of
alternative splicing involving alternative last exon usage15,46, but
the deﬁning event is usage of an intronic alternative poly-
adenylation signal. We performed comprehensive IpA analyses
using 46 3ʹ-seq and RNA-seq samples and identiﬁed 4927 high-
conﬁdence IpA events, the majority of them unannotated. We
found that IpA is unexpectedly widespread and especially com-
mon among normal human immune cells. Expression of IpA
isoforms is often robust—they do not represent ‘cryptic’ events or
‘transcriptional noise’—and is regulated across normal cells and
dysregulated in cancer.
Recently, individual examples of IpA isoforms have been stu-
died in detail, including a truncated protein arising from IpA in
the gene encoding platelet-derived growth factor receptor-α47 and
a non-coding IpA isoform transcribed from the helicase gene
ASCC348. However, the widespread nature of IpA isoform
expression has escaped attention thus far, as RNA-seq analysis
alone is unable to accurately identify mRNA 3ʹ ends. By com-
bining 3ʹ-seq and RNA-seq analyses, we identiﬁed and resolved
the transcript structure of hundreds of new non-coding RNAs as
well as truncated mRNAs predicted to generate proteins with
alternative C termini. The IpA-generated truncated mRNAs are
not subject to degradation by nonsense mediated decay, since
their stop codons are followed by conventional mRNA 3ʹ ends
and hence not premature.
IpA isoform expression is thought to be regulated by compe-
tition between splicing and cleavage-polyadenylation
reactions10,16. Consistent with this model, we found that IpA
genes have distinct structural and sequence properties that may
predispose them toward IpA recognition. IpA genes have longer
introns, longer transcription units, and higher AT content; after
correcting for AT content, IpA genes retain an enrichment of
polyadenylation signals and a depletion of U1 snRNP signals
relative to non-IpA genes23,24. Nevertheless, the tissue-speciﬁc
differential expression of many IpA isoforms also suggests more
complex regulation of production or stability. It is possible that
degradation factors, including components of the RNA exosome,
are downregulated in immune cells, leading to more frequent
IpA49. Alternatively, there may be differential expression of
splicing factors, such as heterogeneous nuclear RNP (hnRNP) C
and U2AF65, involved in the regulation of Alu exonization, a
mechanism known to control the expression of intronic
exons50,51. The fact that more prevalent use of IpA signals,
shorter IpA isoforms, and shorter 3ʹUTRs are all correlated across
tissues suggests that the abundance of the same global co-
transcriptional factors may be partially responsible for all three
properties.
The ﬁnding that long introns and long transcription units are
more susceptible to IpA suggests that the processivity of the co-
transcriptional machinery may also play a role in IpA expression.
Intron retention is a prevalent feature of blood cell
transcriptomes52,53. The tendency to retain certain introns may
provide the polyadenylation machinery time to recognize IpA
signals for cleavage and 3ʹ end processing. Interestingly, we did
ﬁnd a statistically signiﬁcant co-occurrence of introns with IpA
events and retained introns (Supplementary Fig. 8a). Prevalence
of intron retention correlates with prevalence of IpA across cell
types (Supplementary Fig. 8b) and retained introns are enriched
for IpA in each cell type examined (Supplementary Fig. 8c).
However, IpA events in introns with no evidence of intron
retention have higher IpA site usage than those in retained
introns (Supplementary Fig. 8d). Therefore, it is unclear from our
data whether intron retention is a necessary mRNA processing
step prior to IpA recognition and 3ʹ end formation, or whether
IpA recognition can occur independently of intron retention.
A surprising ﬁnding was the enrichment of IpA isoforms at the
5ʹ end of the transcription unit in immune cells. We identiﬁed
469 5ʹIpA isoforms with predicted coding sequence generating
fewer than 100 amino acids. These IpA isoforms are either non-
coding or represent a source of micropeptides28–31. The cellular
function of non-coding RNAs generated through IpA is unclear.
There are reports of promoter-associated RNAs that initiate
upstream of transcription start sites and regulate transcript
expression through RNA interference or interaction with epige-
netic modifying enzymes54–57. However, in matching RNA-seq
data, we did not ﬁnd read evidence upstream of transcription
start sites associated with our predicted non-coding RNAs.
Additionally, CLIP-sequencing data analysis showed that the
exonized intronic sequence of the 5ʹIpA isoforms contains
binding sites for RNA-binding proteins (RBPs); potentially, these
non-coding RNAs serve as scaffolds for RBPs and thereby exert a
regulatory role in trans on other RNAs.
The majority of IpA isoforms (n= 2667), however, are pre-
dicted to generate truncated proteins that retain at least one
domain and have the potential to be functional. Notably, IpA
genes encode larger proteins that contain signiﬁcantly more
Fig. 6 Loss of usage of IpA sites in MM. a Heatmap shown as in Fig. 3b, but for PCs and MM patient samples. MM samples were grouped according to IpA
site usage and color-coded, and the IpA isoforms with signiﬁcantly different usage compared to PCs are shown (FDR-adjusted P < 0.05, lower usage of IpA
sites in MM, n= 480; higher usage of IpA sites in MM, n= 15, not shown). b As in Fig. 3d, but for MM group 1 versus PCs. Full-length and IpA isoform
expression is shown and signiﬁcantly different IpA isoforms are color-coded (FDR-adjusted P < 0.05). c As in Fig. 3b. Shown is a signiﬁcant upregulation of
full-length mRNA isoform expression (one-sided KS test, P < 10−8) of genes highlighted in blue in (b). d Independent set of patients with RNA-seq
expression (n= 286) were classiﬁed into two groups based on the IpA usage of a gene signature (see Methods). Patients in group A-ﬁltered (n= 64)
exhibit loss of recognition of IpA sites, while patients in group B-ﬁltered (n= 100) exhibit higher usage of IpA sites like the PCs. Group B-ﬁltered patients
have signiﬁcantly improved (P < 0.028) progression-free survival than group A patients. e Examples of IpA isoforms expressed in PCs, but signiﬁcantly
decreased in MM samples. Shown as in Fig. 1b. f Validation of expression levels of IpA isoforms from e in terms of usage by qRT-PCR
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domains than proteins generated from non-IpA genes. Strikingly,
proteins encoded by IpA genes are enriched for repeated protein
domains, which in a majority of cases are only partially lost, thus
modulating but not abolishing overall protein function. More-
over, the active sites of enzymes are generally retained in IpA-
generated truncated proteins, again resulting in proteins with
similar function as the full-length proteins but different afﬁnity or
different binding partners. Thus, the cell type-speciﬁc expression
of truncated proteins generated through IpA may be a widely
used mechanism to diversify the proteome, not a peculiarity of a
few well-known examples like IgM.
Although IpA genes avoid membrane proteins overall, IpA can
mimic ectodomain shedding in transmembrane proteins. Metal-
loproteinases such as ADAM10 or ADAM17 are known to release
the ectodomains of several surface receptors, including tumor
necrosis factor-α (TNFα), L-selectin, transforming growth factor-
α, or CD4058,59. In several cases, the soluble ligands act as ago-
nists or antagonists of the membrane-bound ligands; for example,
membrane-bound Fas ligand kills T lymphocytes, while soluble
Fas ligand blocks this activity60. In the vast majority of known
cases, proteolytic cleavage occurs close to the plasma membrane,
cutting at a site near the TMD to release the extracellular domain
of the growth factor receptor or cytokine. Intriguingly, we found
that IpA is another potential mechanism to produce soluble
versions of membrane-bound receptors, as IpA-generated trun-
cations also occur close to the TMD. This suggests that devel-
opmental regulation of membrane-bound versus secreted
molecules—ﬁrst described for IgM—is widespread and can mimic
proteolytic cleavage. For example, IpA can generate soluble TNF
receptor 1, which has been shown to block TNF activity and is
associated with multiple sclerosis61.
It is interesting to speculate why immune cells generate more
IpA isoforms than solid tissues. One possibility is that circulating
immune cells are specialized for secretion of cytokines, and IpA
provides a mechanism for generation of soluble isoforms of
proteins whose full-length isoforms are membrane bound. In
addition, the immune system requires repeated execution of
complex differentiation programs. Perhaps immune cells have
acquired IpA events for specialization of transcriptional and post-
transcriptional programs during cellular differentiation through
partial loss of repeated DNA-binding and RBP domains. An
important example is IKZF1, the gene encoding IKAROS, a
transcription factor whose full-length form is predominantly
expressed in mature B cells. The activity of IKZF1 is known to be
essential for the development of B-cell precursors62, but its DNA-
binding activity appears to be reduced in PCs through a switch to
expression of the apparently non-DNA-binding IpA isoform.
Indeed, IpA isoform expression changes in different stages of
B-cell development and after environmental changes and
importantly is dysregulated in cancer. A majority of the MM
patients that we proﬁled showed a striking loss of IpA isoforms
normally expressed in PCs. As a group, genes that lose IpA
expression in MM samples compared to PCs also upregulate full-
length transcript expression, presumably rescuing the function of
the full-length protein to varying degrees. Here, IZKF1 displays a
switch-like loss of IpA isoform expression and rescue of full-
length transcript expression in MM, providing a key therapeutic
target through Cereblon-mediated degradation by lenalido-
mide35. Intriguingly, some MM patients retain expression of PC
IpA isoforms that may be therapeutically relevant, such as
CUL4A-IpA. CUL4A acts in the DDB1-CUL4A-ROC1 E3 ubi-
quitin ligase complex that interacts with Cereblon to ubiquitinate
and degrade IKZF1. CUL4A-IpA may act as a dominant negative,
able to bind DDB1 but unable to recruit the E2 enzyme required
for substrate ubiquitination. In patients who retain expression of
CUL4A-IpA, although displaying similar IpA usage to PCs
overall, we hypothesize that this truncated protein isoform may
provide a mechanism of resistance to lenalidomide. Interestingly,
not all cancer cells show depletion of IpA isoforms, as we found
increased IpA isoform expression in another B-cell malignancy,
chronic lymphocytic leukemia, reported elsewhere.
Methods
Samples for 3ʹ-seq and RNA-seq analyses. Normal B-cell populations derived
from tissues were obtained from lymphadenectomies performed at Weill Cornell
Medical Center, NY. Blood immune cells were obtained using buffy coats obtained
from the New York Blood Center. Mononuclear cells were obtained using Ficoll
centrifugation. After that, cells were prepared for ﬂuorescence-activated cell sorting
(FACS) to obtain pure populations. Cells were washed with ice-cold phosphate-
buffered saline (PBS) once, incubated with appropriate ﬂuorochrome-conjugated
antibodies for 30 min at 4 °C and washed twice with ice-cold PBS containing 0.5%
fetal calf serum. The following antibodies were used for FACS: anti-CD3-PE
(mouse, BD Biosciences, 555333), anti-CD5-FITC (mouse, BD Biosciences,
555352), anti-CD14-PECy7 (mouse, ebioscience, 25-0149-42), anti-CD19-APC
(mouse, BD Biosciences, 555415), anti-CD27-PE (mouse BD Biosciences, 555441),
anti-CD38-APC (mouse, BD Biosciences, 555462), and anti-CD38-PE (mouse, BD
Biosciences, 555460). The purity of immune cell populations was analyzed by
FACS and the cells were immediately dissolved in TRI Reagent (Ambion) for RNA
extraction, followed by 3ʹ-seq or RNA-seq library preparation. Primary MM cells or
PCs were isolated using Ficoll-Hypaque density gradient sedimentation from bone
marrow aspirates of MM patients or healthy individuals respectively followed by
anti-CD138 microbeads (Milteny Biotech, USA) selection, in accordance with the
Declaration of Helsinki following informed consent and Institutional Review Board
(Dana-Farber Cancer Institute) approval.
3ʹ-seq computational analyses. Preprocessing of 3ʹ-seq libraries, read alignment
(hg19)63, identiﬁcation, and quantiﬁcation of peaks were performed as described
by Lianoglou et al.1. The peaks were assigned to genes using RefSeq annotations.
To obtain an atlas of robust cleavage events in 3ʹUTRs and introns, we started with
all the peaks that were detected by peak calling of all the pooled samples and then
followed a series of steps to ﬁlter lowly expressed peaks and the ones that poten-
tially originate from different artifacts.
Removing artifacts: The peaks potentially resulting from different artifacts were
identiﬁed and removed: (i) peaks overlapping blacklisted regions of human genome
(n= 2841; 0.16%) (https://sites.google.com/site/anshulkundaje/projects/blacklists)
64; (ii) internally primed peaks1 (n= 662,562; 36%); and (iii) antisense peaks (n=
289,340; 16%).
Removing the immunoglobin peaks: Our data set included plasma cells which
are fully differentiated B cells that secrete antibodies. As plasmas cells produce
massive quantities of antibodies, a large fraction of 3ʹ-seq reads mapped to
immunoglobulin loci on chromosomes 2 and 14. It was essential to account for this
skewed expression of speciﬁc genomic regions in order to get a reasonable
quantiﬁcation for the expression of other genes. Thus, peaks (n= 11) overlapping
with parts of the genome coding for immunoglobulins were removed. Even after
this correction, one sample of plasma cells had a high number of intergenic reads
(PC2). Thus, this sample was not used for identiﬁcation of robustly expressed
isoforms but only to quantify them. The library size was reduced accordingly for all
samples, since the peaks described above result either from sequencing artifacts or
from skewed expression of speciﬁc genomic regions.
Removing ambiguous peaks: Some genes in the genome overlap with each
other. In such cases, it is difﬁcult to assign 3ʹ-seq reads to the genes accurately, and
thus such genes (n= 336) were removed from further analysis. This resulted in the
removal of 8437 peaks from the atlas. Since we were interested in investigating the
IpA isoforms of protein coding genes, peaks falling in introns that potentially
originated from microRNAs, small nucleolar RNAs, and retrotransposons were
also removed (n= 4722). Genes that were on the opposite strand but had a 3ʹUTR
end in the intron (100 nt) of a convergent gene can create artifactual antisense
peaks in the intron. Thus, peaks in introns that were close to the end of an opposite
strand 3ʹUTR were also removed (n= 2091). This corresponded to discarding
peaks in the introns of 630 genes. There are genes where the end of the 3ʹUTR
might fall in the intron of the downstream gene on the same strand. This would
also create peaks in introns that are contributed by the preceding gene. Therefore,
peaks in the intron that were within 5000 nt of the 3ʹ end of the 3ʹUTR of the
previous gene were discarded (n= 2079); the discarded peaks came from the
introns of 785 genes.
Identiﬁcation of robust isoforms: The expression levels of IpA and 3ʹUTR ApA
isoforms were quantiﬁed by TPM falling in 3ʹ-seq peaks, i.e., the read count of the
peak regions was normalized by the library size of the respective sample. A gene
can have many cleavage events with adequate expression levels. To examine
cleavage events that represented one of the major isoforms with respect to all
isoforms with a 3ʹ end in a given gene, these isoforms were ﬁltered by usage. Usage
is a statistic that gives an estimate of the relative expression of the isoform. As
different 3ʹUTR ApA isoforms create the same protein irrespective of the 3ʹUTR
length, the usage of IpA isoforms was calculated with respect to the total expression
of 3ʹUTR ApA isoforms. IpA isoforms that end in different introns result in
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distinct protein isoforms (when translated), and therefore their usage was
calculated relative to the total expression of both IpA isoforms and 3ʹUTR
isoforms.
As we were interested in analyzing functionally relevant isoforms, we ﬁltered for
robustly expressed isoforms by imposing TPM and usage cutoffs. For the 3ʹUTR
ApA isoforms, an isoform that was expressed with at least 3 TPM and with usage of
0.1 or more became part of the atlas. To focus on the most conﬁdent IpA isoforms,
an IpA isoform was considered to be robustly expressed only when it was expressed
with 5 TPM or more and had 0.1 usage in at least one sample. The interquartile
range of the start position of the reads was also required to be 5 or more for the
peaks in that particular sample to be deﬁned as a real IpA isoform to eliminate
peaks originating from PCR duplicates. These criteria helped to ﬁlter the lowly
expressed isoforms as well as any possible known artifacts. Filtering for these
expression criteria shrunk the atlas from 410,404 peaks to 46,923. As we were
interested in IpA and 3ʹUTR ApA isoforms that would have different functional
consequences, peaks that were within 200 nt were clustered to represent a single 3ʹ
cleavage event. Clustering reduced the number of peaks to 40,105. After following
the steps above, the atlas comprised 27,927 peaks in 15,670 genes for cleavage
events of the 3ʹUTRs and 3ʹ ends of 5957 IpA isoforms in 3945 genes. For
downstream analysis, we only focused on the IpA isoforms (n= 5670) of protein
coding genes (n= 3768).
Validation and independent read evidence of IpA isoforms. We tried to cor-
roborate the robustly expressed IpA events described thus far (n= 5670) with
external sources of evidence as described below.
1. External annotation: As annotated, we consider mRNA isoforms present in
RefSeq, UCSC, or Ensembl. Last exons of all the existing transcripts of the hg19
annotation for Refseq, UCSC, and Ensembl were obtained. These last exons were
resized to include a region 100 nt downstream of the annotated end. If the 3ʹ end of
the IpA isoform detected by our 3ʹ-seq analysis overlapped with an expanded last
exon, then it was considered to be substantiated by an external annotation. Thus,
39.52% (n= 2241) of all the IpA events fell in the vicinity of annotated 3ʹ end
(using the previous deﬁnition) based on an external annotation.
2. RNA-seq GLM: RNA-seq read coverage is expected only over the exons and
not over the introns, since the splicing machinery splices out introns during co-
transcriptional processing of the pre-mRNA. However, if there is an IpA isoform
that ends in an intron, then there should be RNA-seq read coverage before the 3ʹ
end of the IpA isoform and no read coverage after the 3ʹ end (Fig. 1d). To test
whether the upstream read coverage was signiﬁcantly higher than the downstream
read coverage, two windows of 100 nt separated by 51 nt upstream and
downstream of the IpA 3ʹ end were deﬁned. These two windows served as replicate
bin counts for upstream and downstream coverage. As this was done within each
single RNA-seq sample, library size normalization was not required (i.e., the size
factor was set as 1 for every comparison). Signiﬁcant differential expression
upstream vs. downstream using DESeq17 was then tested (FDR-adjusted P < 0.1).
Not all IpA isoforms could be tested by DESeq. IpA isoforms where the deﬁned
windows overlapped with an annotated exon were excluded from further analysis.
In total, 4802 events were tested. As a control for this analysis, random introns of
expressed genes that did not contain 3ʹ end peaks were sampled and analyzed as
described above. DEseq analysis returned P values consistent with the null
hypothesis (Supplementary Fig. 1a). The RNA-seq validation was applied over all
the RNA-seq samples. If an IpA event was validated in any sample, then it was
considered be supported by RNA-seq data. Of all the IpA isoforms, 29% (n= 1670)
could be validated by this approach.
3. Other 3ʹ end sequencing protocols: If IpA isoforms detected by our 3ʹ-seq
protocol were also found by other 3ʹ-end sequencing methods18, we include the
IpA event in our atlas of high-conﬁdence IpA events. This led to the inclusion of
1332 IpA isoforms. The peaks reported by Gruber et al.18 were resized to be 75 nt
width (25 nt upstream of the original start and 50 nt downstream of the original
start). Overall, 70% (n= 3999) of IpA events were supported by other 3ʹ-end
sequencing protocols.
4. Untemplated adenosines from RNA-seq reads (RNA-seq, polyA reads): In
RNA-seq data, some reads may overlap the 3ʹ end of the templated transcript and
the start of the polyA tail; these reads contain untemplated adenosines and thus fail
to map to the genome. Reads that did not map to the human genome were
therefore used to get additional support for the IpA 3ʹ ends. To make sure that
these reads were at the 3ʹ end, the reads ending with 4 or more As were trimmed.
Only reads that were greater than 21 nt in length after trimming were retained.
Unmapped reads from all RNA-seq samples were trimmed, and all reads with
untemplated As were pooled. These reads were then aligned to the human genome.
Using the aligned BAM ﬁle, all the reads that were possible PCR duplicates were
further ﬁltered out. The uniquely mappable reads that overlapped with the IpA
peak (20 nt extended upstream and downstream) were counted. If an IpA isoform
was supported by four or more trimmed RNA-seq polyA reads together with the
presence of one of the polyadenylation signals (AAUAAA and its variants)65, then
the IpA isoform was considered to be corroborated by polyadenylation RNA-seq
reads.
5. Highly expressed IpA isoforms: Since many of our cell types have not been
previously assayed by other 3ʹ-end sequencing methods and are also not
represented well in existing RNA-seq data sets, we rescued highly expressed cell
type-speciﬁc IpA isoforms by using a stringent expression cutoff (10 TPM and 0.1
usage). We also required the presence of an upstream polyadenylation signal
(AAUAAA and its variants)65. This step enabled us to include 323 IpA events in
the atlas of highly conﬁdent IpA events.
Expression cutoffs used for IpA and full-length mRNA expression. A gene is
considered to be expressed if either the IpA isoform (≥ 5 TPM) or the full-length
isoform (≥ 5.5 TPM) were expressed in 75% of the samples of the particular cell
type.
Conservation analysis. We obtained phastCons 46-way conservation scores21 for
200 nt upstream and downstream of the 3ʹ ends of IpA isoforms to compare the
mean conservation score of the 3ʹ ends of IpA isoforms against random introns
containing polyadenylation signals, but without IpA site usage. The random
introns (n= 5000) were chosen from IpA genes but we selected introns without
IpA events, but with at least one polyadenylation signal (AAUAAA). One of these
polyadenylation signals was randomly selected, and we obtained the phastCons 46-
way conservation score for 200 nt upstream and downstream of this poly-
adenylation signal.
Identiﬁcation of differentially used IpA sites. IpA site usage was calculated as
the fraction of reads that map to the IpA site compared to all the reads that map to
the 3ʹUTR of each gene. This translates into the relative expression of the truncated
protein compared with the full-length protein. To identify the statistically sig-
niﬁcant changes in the usage of pA signals, we used a GLM, where we model the
read counts of all isoforms across conditions by negative binomial distributions
and we test for the signiﬁcance of an interaction term between isoform and con-
dition. This form of modeling approach was adapted from DEXSeq, which is
formulated for testing the differential usage of exons25. If a gene has multiple IpA
isoforms, then the relative expression of each IpA isoform as well as the pooled full-
length mRNA expression were tested independently, since different IpA isoforms
are translated into different protein isoforms.
Gene ontology enrichment analysis. Functional annotation enrichment was
performed on the genes with signiﬁcant differential usage of IpA sites (Fig. 3a)
using DAVID (Database for Annotation, Visualization, and Integrated Discovery)
with the expressed genes as the background26. Functional annotation enrichment
by DAVID was also performed for the genes that loose TMDs and retain TMDs
with all the genes that have TMDs expressing IpA isoforms as background.
Protein domain analysis. The information about protein domains was obtained
from the UCSC UniProt annotation table (spAnnot) via the Bioconductor package-
rtracklayer. Only the domains with annotation type ‘active site’, ‘domain’, ‘trans-
membrane region’, ‘repeat’, ‘zinc ﬁnger region’, ‘compositionally biased region’,
‘DNA-binding region’, ‘region of interest’, ‘lipid moiety-binding region’, ‘short
sequence motif’, ‘calcium-binding region’, ‘nucleotide phosphate-binding region’,
‘metal ion-binding site’, and ‘topological domain’ from UniProt were used for
analysis. These domains were further categorized into more broad categories: (i)
Active site—active site and catalytic sites; (ii) DNA-binding domains—C2H2-type,
PHD-type, C3H1-type, KRAB, Bromo, Chromo, DNA-binding, C4-type, CHCR,
A.T hook, bZIP, bHLH, CCHC-type, CHCH, Bromodomain-like, CH1, C6-type, A.
T hook-like, C4H2-type, and CHHC-type; and (iii) Protein–protein interaction
domains (PPI)—WD, ANK, TPR, LRR, HEAT, Sushi, EF-hand, ARM, PDZ, PH,
SH3, RING-type, LIM zinc-binding, WW, SH2, BTB, FERM, CH, Rod, Coil 1A,
MH2, WD40-like repeat, t-SNARE coiled-coil homology, Coil 1B, Cbl-PTB, Coil,
CARD, SH2-like, DED, IRS-type PTB, SP-RING-type, EF-hand-like, RING-CH-
type, v-SNARE coiled-coil homology, Arm domain, LIM protein-binding, GYF,
PDZ domain-binding, and PDZD11-binding. Also, if a region in protein was
annotated with ‘Interaction with’ then that region was considered a PPI domain,
(iv) RNA-binding domains—RRM, SAM, KH, DRBM, RBD, Piwi, PAZ, S1 motif,
Pumilio, and THUMP; (v) Transmembrane domains (TMDs)—transmembrane
region, ABC transmembrane type-1, ABC transporter and ABC transmembrane
type-2; and (vi) Repeated—any domains that were repeated in the protein were
considered repeated domains. If a gene had multiple protein isoforms, then the
longest isoform was used in the analysis. The protein lengths were obtained from
http://www.uniprot.org/ for Homo sapiens.
Distance of IpA from TMDs. IpA isoforms for which there was positional
information about the start of ﬁrst TMD and those that retained at least one
domain were used for this analysis. Further, we focused on IpA isoforms that
completely lost all their TMDs due to the cleavage event in the intron. The distance
of the retained CDR (in amino acids) by IpA from the ﬁrst TMD was determined
as: (upstream CDR from IpA−upstream CDR from the intron before the ﬁrst
TMD)/3.
De novo transcript assembly. The complete transcript structure was obtained
through the following steps. (i) We used StringTie, an improved method for more
accurate de novo assembly of transcripts from RNA-seq data66. De novo assembly
was performed on every RNA-seq sample with default settings using the hg19
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RefSeq annotation. (ii) Transcripts from multiple assemblies were subsequently
uniﬁed using CuffCompare, which removes redundant transcripts and provides a
set of unique transcript structures67. (iii) For each individual gene, we obtained the
transcripts that overlapped the gene’s coordinates. We gave preference to multi-
exon transcripts over single exon transcripts. For single exon transcripts, we
allowed the start/end to be within 100 nt of the transcription start site (TSS). We
gave this advantage to the single exon transcripts because the direction of tran-
scription for these transcripts is not certain. (iv) Finally, using the 3ʹ ends of IpA
isoforms (from our 3ʹ-seq data), we assigned transcripts with the nearest ends to
these IpA isoforms.
Firstly, we identiﬁed transcripts that ended within 50 nt of 3ʹ-seq events. If there
were several assembled transcripts meeting this criterion, we chose the transcript
that had the maximum number of exons. If there was a tie in the number of exons,
then we chose the transcript that started closest to annotated TSS. For the
remaining 3ʹ-seq events, we assigned the nearest ending transcript. Finally, using
the above deﬁned criteria for selecting transcript structures, we determined which
IpA isoforms corresponded to these assembled transcripts. If the 3ʹ end of the IpA
isoform was within 500 nt of the deﬁned transcript end, then we assumed that this
particular transcript represented the full structure of the IpA isoform. For some
IpA isoforms we observed usage of different polyadenylation signals within the
same intron. Thus, to account for such cases, for the IpA events that did not fall
within 500 nt of a transcript end, we determined if it overlapped a transcript that
ended within 5000 nt. If this was the case, then we assigned this transcript to that 3ʹ
end. We were able to deﬁne the transcript architecture for n= 954 IpA isoforms
(both annotated and unannotated). If the transcripts ends differed from the IpA 3ʹ-
seq events, then we deﬁned the 3ʹ end determined from 3ʹ-seq to be the real end.
This was done as 3ʹ-seq identiﬁes 3ʹ ends of polyadenylated mRNAs at single
nucleotide resolution and thus is more accurate than transcript ends obtained from
short read assembly.
Coding potential prediction. To determine the probability that the 5’IpA events
represented non-coding transcripts, we made use of CPAT, a tool that predicts the
coding potential of the transcript based on four sequence features: ORF size, ORF
coverage, Fickett TESTCODE statistic, and hexamer usage bias27. For our analysis,
we considered non-coding IpA isoforms to be the ones that had coding potential
probability less than 0.3, had retained coding sequence less than 25%, and had ORF
≤ 300 nt (n= 469).
Binding site enrichment of RNA-binding proteins in exonized introns. We used
available CLIP-sequencing data of RNA-binding proteins from doRiNA68. As the
majority of CLIP studies were performed in HEK293 cells, we focused on non-
coding IpA isoforms expressed in HEK293 and only included IpA isoforms in the
analysis whose exonized intron was larger than 50 nt (IpA isoforms= 62, genes=
58).
We determined if the exonized part of the intron was enriched for binding sites
of RNA-binding proteins compared to other regions (introns, coding exons,
3ʹUTRs) of the transcription units, called ‘background’ here. We calculated the
expected number of binding sites in the exonized introns using each background
and compared it to the observed number of binding sites in the exonized introns.
This enabled us to calculate a binomial Z-score of each CLIP experiment and each
background region. We observed enrichment of binding sites of RNA-binding
proteins in the exonized introns compared with introns and coding exons but no
enrichment compared to 3ʹUTRs. The RNA-binding proteins with Z-scores ≥10
compared to introns or coding exons are PUM2, FUS, ELAVL1, TIAL1, and
TAF15.
qRT-PCR experiments. cDNA was synthesized from 200 to 1000 ng of total RNA
using a SuperScript VILO cDNA Synthesis Kit (Invitrogen, cat no: 11754050) and
random primers. qRT-PCR was performed using SYBR Green PCR Master Mix
(Applied Biosystems, cat no: 4309155) on an Applied Biosystems PRISM 7900HT
real-time RT-PCR machine using the following primers:
● CUL4A-IpA-F1: TCGTCCCGTTTGTGTCTTCC
● CUL4A- IpA-R1: CCACCTGGACTCCTACGTTC
● CUL4A-full-length-F1: TGGAGAGAGACAAAGACAATCCG
● CUL4A- full-length-R1: TCATGAAGGGGAACCGTCTG
● IQGAP1-IpA-F1: GAGACGTCAGAACGTGGCTTA
● IQGAP1-IpA-R1: AATCTTCTCTCCAGCCAGCC
● IQGAP1-full-length-F1: GACCTAGCCAACAACAGCAC
● IQGAP1-full-length-R1: ACAAATGTCCCATCAGAGCGA
● IKZF1-IpA-F1: TGGGGCTGATGACTTTAGGGA
● IKZF1-IpA-R1: AGTAGCCGCTTGTGTGAGAA
● IKZF1-full-length-F1: TTCCGTGATCCTTTTGAGTGC
● IKZF1- full-length-R1: CTCGCGTTATGTGCGACGA
Data are represented as the ratio of 2−ΔΔCTIpA/(2−ΔΔCTIpA+ 2−ΔΔCTfull-length)
for each sample.
Progression-free survival analysis. An independent cohort of 319 RNA-seq of
MM patients with progression-free survival data for 286 patients was used for this
analysis. IpA usage of the isoforms was calculated using RNA-seq data. Expression
of IpA isoforms was deﬁned as length normalized reads counts that mapped within
500 bp upstream or n bps (at least 50 bp) without running into an upstream exon
from the end 3ʹ-seq peak. Similarly, full-length expression was deﬁned as length
normalized reads counts within 500 bp region from the start of the last coding exon
of the gene. IpA isoforms that had signiﬁcantly differential usage (FDR-adjusted P
< 0.05) in MM when compared to PCs with the difference in usage >0.25 were used
(n= 114). Only the IpA isoforms that had Pearson's correlation r > 0.75 (n= 28)
were used to deﬁne the gene signature. Using this gene signature the patient cohort
was deﬁned segregated in two groups with low and high IpA usage, 139 and 176
respectively. Progression-free survival data were available for a subset of these
patients in group A (n= 126) and group B (n= 160). Heterogeneous samples from
the two groups were removed based on the group of neighboring samples. For
every sample, the nearest ﬁve samples were determined based on the Euclidean
distance and the sample for which the nearest 80% samples had the same group
were retained, group A-ﬁltered (n= 73) and group B-ﬁltered (n= 115).
Progression-free survival data were available for a subset of these patients in group
A-ﬁltered (n= 64) and group B-ﬁltered (n= 100). The R survival package was
used to perform the Kaplan–Meier analysis for the two groups.
Identiﬁcation of retained introns. Retained introns were identiﬁed using a
modiﬁed version of the IRFinder algorithm52. To avoid genes with a complex
genomic architecture, we removed genes that overlap with other genes in either the
sense of antisense strand. An intron was categorized as retained if it satisﬁed the
following criteria. (i) There should be at least three reads spanning both the
upstream and downstream exon–intron junction. (ii) At least 50% of the intron
length should be covered by 3 or more unique reads. Mappability of introns could
be a limitation in this case, and thus we focused only on introns that had at least
50% uniquely mappable sequence relative to its complete length. (iii) To ensure
adequate expression of the ﬂanking exons, the median coverage over the ﬂanking
exons was required to be 10 reads or more. (iv) Since the introns should have more
coverage than background noise, we considered introns to be retained if the ratio of
median coverage over the intron to median coverage of the upstream and down-
stream exons was at least 10%.
An intron was annotated as retained if it fulﬁlled all criteria in at least 66% of
the RNA-seq samples of a given cell type. Introns retained in 33% or fewer samples
were ﬂagged as not retained while the introns that were retained in more than 33%
samples but less than 66% of RNA-seq samples were removed from the analysis.
For a 3ʹ end of an IpA isoform to occur in a particular intron, the intron must
contain a polyadenylation signal or one of its variants65.
Our data showed that some genes had very high coverage over almost all the
introns of the gene, presumably due to sequencing artifacts. We determined the
(median coverage over all the introns)/(median coverage over all the exons), and if
this ratio was ≥0.2 then these genes were ﬂagged for removal.
The number of introns that would have IpA and IR simultaneously by chance
were calculated as: probability of IpA × probability of IR × number of expressed
introns with polyadenylation signal.
Data availability. All 3ʹ-seq and RNA-seq data generated for this study have been
deposited in the Gene Expression Omnibus database under accession number
GSE111310.
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